Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
1 cost-effectiveness analysis and 0 studies reporting utility weights · 1 source
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 1 |
| Studies reporting utility weights | 0 |
Cost-effectiveness analyses
Analyses of QTORIN rapamycin 3.9 percent gel
No evidence found.
Treatments for the same indication
No evidence found.
The same disease in other populations or settings
Sirolimus versus supportive care in slow-flow vascular malformations, Australia: Li and Sebaratnam (2024)
Relevance: A cost-utility analysis of sirolimus in vascular malformations in Australia, the systemic mTOR inhibitor that section 2 lists for lymphatic malformations.
“The cost‐utility decision analysis modelled a simulated population of Australian patients aged ≥18 years with slow flow vascular malformations requiring treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the model, patients were either initiated on sirolimus 1 mg daily or received supportive care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis employed a decision‐tree model developed with TreeAge Pro Software (Version 2024 R1.1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only direct costs were included, as per convention of cost‐utility analyses adopting a healthcare sector perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were reported in August 2024 AU$. Discounting was not applied given the short time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a one‐year time horizon, sirolimus was associated with increased expenditure of AU$2832.80 and a gain of 0.08 QALYs, yielding an ICER of AU$35,410/QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilistic sensitivity analyses indicated that relative to the AU$50,000/QALY threshold, base‐case sirolimus was more cost‐effective compared to supportive care in 55.1% of the 10,000 iterations of the Monte Carlo simulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Related diseases and analogous treatments
No evidence found.
Utility weights
Utility weights from analyses of QTORIN rapamycin 3.9 percent gel
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
No evidence found.
Utility weights for related diseases and analogous treatments
No evidence found.
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Methods | QTORIN OR rapamycin OR sirolimus | 20 |
| Ratios | "lymphatic malformation" OR "lymphatic malformations" OR lymphangioma OR "cystic hygroma" | 0 |
| Methods | "vascular malformation" OR "vascular malformations" OR "vascular anomalies" OR "lymphatic malformation" | 2 |
| Weights | lymphatic OR lymphangioma OR "vascular malformation" OR "vascular malformations" | 9 |
| Ratios | angiofibroma OR "tuberous sclerosis" OR "topical sirolimus" OR "topical rapamycin" | 4 |
| Ratios | hemangioma OR haemangioma OR "port-wine" OR "port wine" | 0 |
| Ratios | lymphangioleiomyomatosis OR "PIK3CA" OR alpelisib OR "PROS" | 21 |
| Ratios | "epidermolysis bullosa" OR "birch bark" OR "beremagene" | 0 |
| Ratios | sclerotherapy AND (malformation OR cyst) | 0 |